Cortexyme (NASDAQ:CRTX – Get Rating) and Elevation Oncology (NASDAQ:ELEV – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends. Earnings and Valuation This table compares Cortexyme and Elevation Oncology’s […]
10.05.2022 - Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement under which the company plans to acquire . Seite 1
Cortexyme (NASDAQ:CRTX – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports. According to Zacks, “Cortexyme Inc. is a clinical-stage biopharmaceutical company. It is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The company’s drug candidate […]
Shares of Cortexyme, Inc. (NASDAQ:CRTX – Get Rating) have earned a consensus recommendation of “Hold” from the eight brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. […]